Tommaso Bianchelli
Ancona, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 34 publications
Beneficial effects of upadacitinib on a subgroup of patients with atopic dermatitis and hidradenitis suppurativa: a multicenter, real-world retrospective study.
Journal: Frontiers in immunology
Published: December 18, 2025
Forty-eight-week safety of bimekizumab in psoriasis: focus on infectious comorbidities.
Journal: Italian journal of dermatology and venereology
Published: December 11, 2025
Real-World Efficacy of IL-23 Inhibitors in Psoriasis Affecting High-Impact Areas: Indirect Comparison of Tildrakizumab 200 mg, Risankizumab, and Guselkumab-IL PSO (Italian Landscape Psoriasis).
Journal: Dermatology and therapy
Published: December 01, 2025
Early dermoscopic and confocal features predict response to topical ruxolitinib in nonsegmental vitiligo: A prospective observational study.
Journal: Journal of the American Academy of Dermatology
Published: July 17, 2025
Long-Term Real-World Effectiveness and Drug Survival of Guselkumab in Patients with Psoriasis: A 5-Year Retrospective Study.
Journal: Psoriasis (Auckland, N.Z.)
Published: April 08, 2025
Gender Influence on Bimekizumab Response in Patients with Psoriasis: Results of a Real-World Multicenter Retrospective Study-IL PSO (Italian Landscape PSOriasis).
Journal: Dermatology and therapy
Published: March 10, 2025
Effectiveness of Tildrakizumab 200 mg in Moderate-to-Severe Plaque Psoriasis: A Multicenter Real-World Study Analyzing Patient Outcomes by Weight, PASI, BMI, and Previous Therapies.
Journal: Dermatology and therapy
Published: March 02, 2025
Predictive Factors for Super Responder Status and Long-Term Effectiveness of Guselkumab in Psoriasis: A Multicenter Retrospective Study.
Journal: Dermatology and therapy
Published: February 24, 2025
A long-term real-world safety study of guselkumab in patients with psoriasis who have infectious comorbidities, malignancies or heart disease: the EARLY study.
Journal: Clinical and experimental dermatology
Published: February 19, 2025
Effectiveness of Tralokinumab Across Atopic Dermatitis Phenotypes.
Journal: Journal of clinical medicine
Published: February 05, 2025
BRodalumab effectiveness in psoriatic patients that experienced anti-IL17 Intra-Class failure: a multicentre, retrospective study (BRIC - Study) IL-PSO (Italian Landscape Psoriasis).
Journal: Clinical and experimental dermatology
Published: January 17, 2025
Effectiveness of Brodalumab for the Treatment of Moderate-to-Severe Psoriasis: A Retrospective, Real-World Multicenter Study with a Focus on Obese and Multi-Failure Patients-IL PSO (Italian Landscape Psoriasis).
Journal: Journal of clinical medicine
Published: December 31, 2024
Last Updated: 09/26/2026